Nov 27, 2022
Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a day after receiving U.S. approval and far higher than some analysts' expectations.
seen from Maldives
seen from United States
seen from Argentina
seen from Malaysia
seen from United States
seen from United States
seen from Malaysia
seen from United States
seen from Germany
seen from Israel
seen from France
seen from United States
seen from United States
seen from United States
seen from United States
seen from Netherlands
seen from United States
seen from China
seen from United States
seen from United States
Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a day after receiving U.S. approval and far higher than some analysts' expectations.
Provention Bio sets terms for $50 million best-efforts IPO Provention Bio which is developing novel therapies for autoimmune and inflammatory diseases announced terms for its IPO on Wednesday The deal is being conducted on a best efforts basis and is therefore excluded from Renaissance Capital s IPO stats The Oldwick NJ based company plans... Latest Articles in
You have been given this life because you are strong enough to live it.